Overall, these data suggest that pancreatic cancers with loss of SMAD4 represent a poorly immunogenic molecular subtype, with a relative lack of T-cell infiltration and limited expression of PD-L1. This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.